^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    CD30 biAb-AATC

    i
    Other names: CD30 biAb-AATC, anti-CD30 Bispecific Antibody-armed anti-CD3-Activated Autologous T-cells
    Associations

    News

    Trials
    Company:
    Medical College of Wisconsin, Tundra Targeted Therap
    Drug class:
    CD3 agonist, T-cell stimulant, CD30 inhibitor
    Related drugs:
    Associations

    News

    Trials
    6ms
    CD30biAb-AATC for CD30+ Malignancies (clinicaltrials.gov)
    P1, N=42, Not yet recruiting, Medical College of Wisconsin | Phase classification: P1/2 --> P1 | Trial completion date: Jan 2027 --> Jul 2028
    Phase classification • Trial completion date
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    TNFRSF8 expression
    |
    CD30 biAb-AATC • Leukine (sargramostim)
    3years
    CD30biAb-AATC for CD30+ Malignancies (clinicaltrials.gov)
    P1/2, N=42, Not yet recruiting, Medical College of Wisconsin
    New P1/2 trial
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8) • CSF2 (Colony stimulating factor 2)
    |
    TNFRSF8 expression
    |
    CD30 biAb-AATC